Skip to content
DataLookout
Menu

ProbENCT07100743

Trial of Multi-Strain Probiotic Supplementation (Hexbio®) in Malaysian Patients With Drug-Resistant Epilepsy (ProbE)

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 5 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Trial completed
    • Secondary endpoint revised
    • Study description expanded, about 17 words
    • Collaborator revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

To compare the quality of life score pre and post administration of probiotics
Timeframe: 2 months

Secondary (1)

To assess the seizure Frequency pre and post administration of probiotics

Arms and interventions

InterventionActive comparator

HEXBIO MCP Granule probiotic is prepared in sachets which consist of the following probiotics: Lactobacillus acidophilus (BCMC 1 12130)107mg, Lactobacillus casei (BCMC 1 12313) -107mg, Lactobacillus lactis (BCMC 1 12451)-107 mg, (BCMC 1 02290) -107mg, Bifidobacterium infantis (BCMC 1 02129) -107mg and Bifidobacterium longum (BCMC 102120)-107mg. Patients will be instructed to consume one sachet directly before meal (drink water if needed) twice daily, for two months.

PlaceboPlacebo comparator

The placebo sachets will contain the same ingredient as the probiotic sachet but without the Lactobacillus sp. and Bifidobacterium sp. Participants in the placebo group will receive an identical Hexbio sachet (aluminum foil sachet.) with non-microbial material.

Dietary supplements: Probiotic Agent, Placebo

Sites

1 site in 1 country

  • National University of MalaysiaKuala Lumpur, Malaysia